TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
CRVS

Corvus Pharmaceuticals Inc

Healthcare · Biotechnology

9.70$ -3.3% vs. previous close Closing price · As of: Nov 2, 2026

Ownership

Ownership Structure

Who owns Corvus Pharmaceuticals Inc (CRVS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 86.5% of the shares are freely tradable; institutional investors hold 85.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 85.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 3.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 86.5%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 24.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 84Mio.

Largest Shareholders

Institutions

Institutions CRVS
Name Stake (%) Shares Change (%) Date
Orbimed Advisors LLC 8.52 7,165,006 +0.0 06/30/2026
BlackRock Inc 8.49 7,138,811 +15.9 06/30/2026
State Street Corp 5.32 4,474,091 +25.5 06/30/2026
T. Rowe Price Associates, Inc. 4.50 3,789,126 +29.9 06/30/2026
Vanguard Capital Management, LLC 3.91 3,292,710 +1.8 06/30/2026
Adams Street Partners LLC 3.89 3,275,616 +0.0 06/30/2026
Vivo Capital, LLC 3.34 2,805,816 +0.0 06/30/2026
Wellington Management Company LLP 3.25 2,731,632 +17.8 06/30/2026
Perceptive Advisors LLC 3.17 2,667,441 +16.4 06/30/2026
Deep Track Capital, LP 2.96 2,491,939 +0.0 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?